1301 related articles for article (PubMed ID: 34108716)
1. Impact of vaccination on new SARS-CoV-2 infections in the United Kingdom.
Pritchard E; Matthews PC; Stoesser N; Eyre DW; Gethings O; Vihta KD; Jones J; House T; VanSteenHouse H; Bell I; Bell JI; Newton JN; Farrar J; Diamond I; Rourke E; Studley R; Crook D; Peto TEA; Walker AS; Pouwels KB
Nat Med; 2021 Aug; 27(8):1370-1378. PubMed ID: 34108716
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study.
Lopez Bernal J; Andrews N; Gower C; Robertson C; Stowe J; Tessier E; Simmons R; Cottrell S; Roberts R; O'Doherty M; Brown K; Cameron C; Stockton D; McMenamin J; Ramsay M
BMJ; 2021 May; 373():n1088. PubMed ID: 33985964
[TBL] [Abstract][Full Text] [Related]
3. Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and SARS-CoV-2 positive testing: self-controlled case series study.
Hippisley-Cox J; Patone M; Mei XW; Saatci D; Dixon S; Khunti K; Zaccardi F; Watkinson P; Shankar-Hari M; Doidge J; Harrison DA; Griffin SJ; Sheikh A; Coupland CAC
BMJ; 2021 Aug; 374():n1931. PubMed ID: 34446426
[TBL] [Abstract][Full Text] [Related]
4. Effect of Pfizer/BioNTech and Oxford/AstraZeneca vaccines against COVID-19 morbidity and mortality in real-world settings at countrywide vaccination campaign in Saudi Arabia.
Meo SA; Fahad Al-Jassir F; Al-Qahtani S; Albarrak R; Usmani AM; Klonoff DC
Eur Rev Med Pharmacol Sci; 2021 Nov; 25(22):7185-7191. PubMed ID: 34859883
[TBL] [Abstract][Full Text] [Related]
5. Effect of Delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK.
Pouwels KB; Pritchard E; Matthews PC; Stoesser N; Eyre DW; Vihta KD; House T; Hay J; Bell JI; Newton JN; Farrar J; Crook D; Cook D; Rourke E; Studley R; Peto TEA; Diamond I; Walker AS
Nat Med; 2021 Dec; 27(12):2127-2135. PubMed ID: 34650248
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of the BNT162b2 (Pfizer-BioNTech) and the ChAdOx1 nCoV-19 (Oxford-AstraZeneca) vaccines for reducing susceptibility to infection with the Delta variant (B.1.617.2) of SARS-CoV-2.
Pattni K; Hungerford D; Adams S; Buchan I; Cheyne CP; García-Fiñana M; Hall I; Hughes DM; Overton CE; Zhang X; Sharkey KJ
BMC Infect Dis; 2022 Mar; 22(1):270. PubMed ID: 35307024
[TBL] [Abstract][Full Text] [Related]
7. BNT162b2 and ChAdOx1 SARS-CoV-2 Post-vaccination Side-Effects Among Saudi Vaccinees.
Alghamdi AN; Alotaibi MI; Alqahtani AS; Al Aboud D; Abdel-Moneim AS
Front Med (Lausanne); 2021; 8():760047. PubMed ID: 34692740
[No Abstract] [Full Text] [Related]
8. Anti-Coronavirus Vaccines: Past Investigations on SARS-CoV-1 and MERS-CoV, the Approved Vaccines from BioNTech/Pfizer, Moderna, Oxford/AstraZeneca and others under Development Against SARSCoV- 2 Infection.
Costanzo M; De Giglio MAR; Roviello GN
Curr Med Chem; 2022; 29(1):4-18. PubMed ID: 34355678
[TBL] [Abstract][Full Text] [Related]
9. Coincidental Onset of Ocular Myasthenia Gravis Following ChAdOx1 n-CoV-19 Vaccine against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Galassi G; Rispoli V; Iori E; Ariatti A; Marchioni A
Isr Med Assoc J; 2022 Jan; 24(1):9-10. PubMed ID: 35077038
[TBL] [Abstract][Full Text] [Related]
10. A Case Report of Immune Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination.
Kim G; Choi EJ; Park HS; Lee JH; Lee JH; Lee KH
J Korean Med Sci; 2021 Nov; 36(43):e306. PubMed ID: 34751013
[TBL] [Abstract][Full Text] [Related]
11. BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers.
Lustig Y; Sapir E; Regev-Yochay G; Cohen C; Fluss R; Olmer L; Indenbaum V; Mandelboim M; Doolman R; Amit S; Mendelson E; Ziv A; Huppert A; Rubin C; Freedman L; Kreiss Y
Lancet Respir Med; 2021 Sep; 9(9):999-1009. PubMed ID: 34224675
[TBL] [Abstract][Full Text] [Related]
12. Delayed Cutaneous Hypersensitivity Reaction to Vaxzevria (ChAdOx1-S) Vaccine against SARS-CoV-2.
Sprute R; Schumacher S; Pauls M; Pauls W; Cornely OA
Drugs R D; 2021 Dec; 21(4):371-374. PubMed ID: 34351606
[TBL] [Abstract][Full Text] [Related]
13. Antibody responses after a single dose of ChAdOx1 nCoV-19 vaccine in healthcare workers previously infected with SARS-CoV-2.
Havervall S; Marking U; Greilert-Norin N; Ng H; Gordon M; Salomonsson AC; Hellström C; Pin E; Blom K; Mangsbo S; Phillipson M; Klingström J; Hober S; Nilsson P; Åberg M; Thålin C
EBioMedicine; 2021 Aug; 70():103523. PubMed ID: 34391088
[TBL] [Abstract][Full Text] [Related]
14. Disentangling post-vaccination symptoms from early COVID-19.
Canas LS; Österdahl MF; Deng J; Hu C; Selvachandran S; Polidori L; May A; Molteni E; Murray B; Chen L; Kerfoot E; Klaser K; Antonelli M; Hammers A; Spector T; Ourselin S; Steves C; Sudre CH; Modat M; Duncan EL
EClinicalMedicine; 2021 Dec; 42():101212. PubMed ID: 34873584
[TBL] [Abstract][Full Text] [Related]
15. Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study.
Maneikis K; Šablauskas K; Ringelevičiūtė U; Vaitekėnaitė V; Čekauskienė R; Kryžauskaitė L; Naumovas D; Banys V; Pečeliūnas V; Beinortas T; Griškevičius L
Lancet Haematol; 2021 Aug; 8(8):e583-e592. PubMed ID: 34224668
[TBL] [Abstract][Full Text] [Related]
16. A single dose of the Biontech/Pfizer BNT162b2 vaccine protected elderly residents from severe COVID-19 during a SARS-coronavirus-2 outbreak in a senior citizen home in Germany.
Schwarzer R; Freys SD; Neuwinger N; Beikert N; Eberspächer B; Edelmann A; Zuchowski M; Slothouwer I; Stein A; Theil K; Menzel P; Hofmann J
Immun Inflamm Dis; 2021 Dec; 9(4):1809-1814. PubMed ID: 34528766
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Frontline Workers Before and During B.1.617.2 (Delta) Variant Predominance - Eight U.S. Locations, December 2020-August 2021.
Fowlkes A; Gaglani M; Groover K; Thiese MS; Tyner H; Ellingson K;
MMWR Morb Mortal Wkly Rep; 2021 Aug; 70(34):1167-1169. PubMed ID: 34437521
[TBL] [Abstract][Full Text] [Related]
18. Thrombosis and thrombocytopenia after vaccination against and infection with SARS-CoV-2 in the United Kingdom.
Burn E; Li X; Delmestri A; Jones N; Duarte-Salles T; Reyes C; Martinez-Hernandez E; Marti E; Verhamme KMC; Rijnbeek PR; Strauss VY; Prieto-Alhambra D
Nat Commun; 2022 Nov; 13(1):7167. PubMed ID: 36418291
[TBL] [Abstract][Full Text] [Related]
19. Assessment of Effectiveness of 1 Dose of BNT162b2 Vaccine for SARS-CoV-2 Infection 13 to 24 Days After Immunization.
Chodick G; Tene L; Patalon T; Gazit S; Ben Tov A; Cohen D; Muhsen K
JAMA Netw Open; 2021 Jun; 4(6):e2115985. PubMed ID: 34097044
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity of a first dose of mRNA- or vector-based SARS-CoV-2 vaccination in dialysis patients: a multicenter prospective observational pilot study.
Lesny P; Anderson M; Cloherty G; Stec M; Haase-Fielitz A; Haarhaus M; Santos C; Lucas C; Macario F; Haase M
J Nephrol; 2021 Aug; 34(4):975-983. PubMed ID: 34050904
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
